Business Context and Reporting Period
This Form 8-K is a current report filed by BioRestorative Therapies, Inc. (BRTX) on September 4, 2026. The filing addresses the immediate resignation of Mr. Silva, the Company's Vice President of Research and Development, and a related dispute regarding his employment agreement and severance claims.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a potential contingent liability:
- Potential Severance Liability: Approximately $1.29 million in cash severance payments, plus acceleration of equity awards and benefits, if the resignation is deemed to be for "Good Reason" under the disputed Employment Agreement.
Material Changes and Disputes
The primary material event is the resignation of Mr. Silva, who asserts his departure qualifies as a resignation for "Good Reason" due to a "Change in Control" resulting from Board composition changes in June 2026 linked to a Revolving Loan Agreement with Bowery Group LLC. The Company disputes these assertions:
- The Board has not accepted the validity of the Employment Agreement or the characterization of the resignation.
- The Company has reserved all rights, claims, and defenses against the severance demand.
- Payments are currently limited to accrued and unpaid base salary through the date of cessation of service and amounts required by wage-payment laws.
Outlook, Risks, and Contingencies
Investigation: The Board has authorized an investigation by special counsel into the negotiation, approval, execution, and amendment of Mr. Silva's Employment Agreement, as well as agreements with the former CEO and CFO.
Risk: There is a contingency regarding the potential payout of approximately $1.29 million plus equity acceleration if the investigation or legal proceedings validate Mr. Silva's claims.
Management Commentary: The filing is signed by Mika Grasso, the Interim Chief Executive Officer, indicating ongoing leadership transition or instability.
Key Facts for Investor Verification
- Verify the status of the special counsel investigation into the Employment Agreement and the June 2026 Board changes.
- Monitor for any legal filings or settlements regarding the $1.29 million severance claim.
- Confirm the current composition of the Board of Directors and the status of the Revolving Loan Agreement with Bowery Group LLC.
- Assess the impact of the VP of R&D departure on the Company's research pipeline and operational continuity.